Skip to main content

Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants

The comparative risk for gastrointestinal bleeding (GIB) with non-vitamin K antagonist oral anticoagulants (NOACs) was compared to vitamin K antagonists or anti-platelet agents in a recent metanalysis, which showed no significant difference in major GIB events between these agents.

A systematic review focused on 43 randomized controlled trials, 183,752 patients and 41 real-world studies (1,879,428 patients). NOACs include popular drugs such as  dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis). 

The pooled major rates of GIB were:

  • NOACs 1.19%
  • Conventional treatment 0.92%

Comparative results were not significant in randomized controlled trials or from real-world studies.

Rivaroxaban, but not other NOACs, was associated with an increased risk for major GIB (RR 1.39; 95% CI, 1.17-1.65 and RR 1.14; 95% CI, 1.04-1.23).

 

 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject